c-erbB-4 protein expression in human breast cancer

Thean Yean Kew, J. A. Bell, S. E. Pinder, H. Denley, R. Srinivasan, W. J. Gullick, R. I. Nicholson, R. W. Blamey, I. O. Ellis

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

The Type 1 family of growth factor receptors includes epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3 and c-erbB-4. Overexpression of the first two members is associated with poorer prognosis in patients with breast carcinoma. In this study we examined the expression of c-erbB-4 protein using the monoclonal antibody HFR-1. A total of 127 consecutive cases of primary operable invasive breast carcinoma presenting between 1975 and 1977 were studied. All patients were managed by simple mastectomy or conservation surgery with radiotherapy and no adjuvant therapy given. Long-term follow-up was maintained. Routine, formalin-fixed, paraffin-embedded tumour samples were used and sections were stained immunohistochemically using the Duet StreptABC method. Immunoreactivity was classified using a simple semi-quantitative scoring method. Protein expression was generally low but definite positive cytoplasmic, membranous and nuclear reactivity was identified in 58%, 41% and 25% of cases respectively. Expression at all three sites demonstrated significant inverse associations were histological grade. In addition, membrane accentuation correlated inversely with the Nottingham Prognostic Index (NPI), while cytoplasmic reactivity showed a positive association with c-erbB-3 expression. No significant associations were found with disease-free interval or survival. The results of this study demonstrate that higher levels of c-erbB-4 protein expression are associated with a more differentiated histological phenotype in contrast to the other members of the Type 1 family. Larger series with extended follow-up will be required to ascertain definitively the prognostic value of c-erbB-4 expression in breast carcinoma. (C) 2000 Cancer Research Campaign.

Original languageEnglish
Pages (from-to)1163-1170
Number of pages8
JournalBritish Journal of Cancer
Volume82
Issue number6
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Breast Neoplasms
Simple Mastectomy
Adjuvant Radiotherapy
Growth Factor Receptors
Epidermal Growth Factor Receptor
Paraffin
Formaldehyde
Research Design
Monoclonal Antibodies
Phenotype
Membranes
Survival
ErbB-4 Receptor
Neoplasms
Proteins
Therapeutics

Keywords

  • Breast cancer
  • c-erbB-4
  • Growth factor receptor
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kew, T. Y., Bell, J. A., Pinder, S. E., Denley, H., Srinivasan, R., Gullick, W. J., ... Ellis, I. O. (2000). c-erbB-4 protein expression in human breast cancer. British Journal of Cancer, 82(6), 1163-1170.

c-erbB-4 protein expression in human breast cancer. / Kew, Thean Yean; Bell, J. A.; Pinder, S. E.; Denley, H.; Srinivasan, R.; Gullick, W. J.; Nicholson, R. I.; Blamey, R. W.; Ellis, I. O.

In: British Journal of Cancer, Vol. 82, No. 6, 2000, p. 1163-1170.

Research output: Contribution to journalArticle

Kew, TY, Bell, JA, Pinder, SE, Denley, H, Srinivasan, R, Gullick, WJ, Nicholson, RI, Blamey, RW & Ellis, IO 2000, 'c-erbB-4 protein expression in human breast cancer', British Journal of Cancer, vol. 82, no. 6, pp. 1163-1170.
Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, Gullick WJ et al. c-erbB-4 protein expression in human breast cancer. British Journal of Cancer. 2000;82(6):1163-1170.
Kew, Thean Yean ; Bell, J. A. ; Pinder, S. E. ; Denley, H. ; Srinivasan, R. ; Gullick, W. J. ; Nicholson, R. I. ; Blamey, R. W. ; Ellis, I. O. / c-erbB-4 protein expression in human breast cancer. In: British Journal of Cancer. 2000 ; Vol. 82, No. 6. pp. 1163-1170.
@article{a524470e2604434895b608dac0dcfc90,
title = "c-erbB-4 protein expression in human breast cancer",
abstract = "The Type 1 family of growth factor receptors includes epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3 and c-erbB-4. Overexpression of the first two members is associated with poorer prognosis in patients with breast carcinoma. In this study we examined the expression of c-erbB-4 protein using the monoclonal antibody HFR-1. A total of 127 consecutive cases of primary operable invasive breast carcinoma presenting between 1975 and 1977 were studied. All patients were managed by simple mastectomy or conservation surgery with radiotherapy and no adjuvant therapy given. Long-term follow-up was maintained. Routine, formalin-fixed, paraffin-embedded tumour samples were used and sections were stained immunohistochemically using the Duet StreptABC method. Immunoreactivity was classified using a simple semi-quantitative scoring method. Protein expression was generally low but definite positive cytoplasmic, membranous and nuclear reactivity was identified in 58{\%}, 41{\%} and 25{\%} of cases respectively. Expression at all three sites demonstrated significant inverse associations were histological grade. In addition, membrane accentuation correlated inversely with the Nottingham Prognostic Index (NPI), while cytoplasmic reactivity showed a positive association with c-erbB-3 expression. No significant associations were found with disease-free interval or survival. The results of this study demonstrate that higher levels of c-erbB-4 protein expression are associated with a more differentiated histological phenotype in contrast to the other members of the Type 1 family. Larger series with extended follow-up will be required to ascertain definitively the prognostic value of c-erbB-4 expression in breast carcinoma. (C) 2000 Cancer Research Campaign.",
keywords = "Breast cancer, c-erbB-4, Growth factor receptor, Prognostic factors",
author = "Kew, {Thean Yean} and Bell, {J. A.} and Pinder, {S. E.} and H. Denley and R. Srinivasan and Gullick, {W. J.} and Nicholson, {R. I.} and Blamey, {R. W.} and Ellis, {I. O.}",
year = "2000",
language = "English",
volume = "82",
pages = "1163--1170",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - c-erbB-4 protein expression in human breast cancer

AU - Kew, Thean Yean

AU - Bell, J. A.

AU - Pinder, S. E.

AU - Denley, H.

AU - Srinivasan, R.

AU - Gullick, W. J.

AU - Nicholson, R. I.

AU - Blamey, R. W.

AU - Ellis, I. O.

PY - 2000

Y1 - 2000

N2 - The Type 1 family of growth factor receptors includes epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3 and c-erbB-4. Overexpression of the first two members is associated with poorer prognosis in patients with breast carcinoma. In this study we examined the expression of c-erbB-4 protein using the monoclonal antibody HFR-1. A total of 127 consecutive cases of primary operable invasive breast carcinoma presenting between 1975 and 1977 were studied. All patients were managed by simple mastectomy or conservation surgery with radiotherapy and no adjuvant therapy given. Long-term follow-up was maintained. Routine, formalin-fixed, paraffin-embedded tumour samples were used and sections were stained immunohistochemically using the Duet StreptABC method. Immunoreactivity was classified using a simple semi-quantitative scoring method. Protein expression was generally low but definite positive cytoplasmic, membranous and nuclear reactivity was identified in 58%, 41% and 25% of cases respectively. Expression at all three sites demonstrated significant inverse associations were histological grade. In addition, membrane accentuation correlated inversely with the Nottingham Prognostic Index (NPI), while cytoplasmic reactivity showed a positive association with c-erbB-3 expression. No significant associations were found with disease-free interval or survival. The results of this study demonstrate that higher levels of c-erbB-4 protein expression are associated with a more differentiated histological phenotype in contrast to the other members of the Type 1 family. Larger series with extended follow-up will be required to ascertain definitively the prognostic value of c-erbB-4 expression in breast carcinoma. (C) 2000 Cancer Research Campaign.

AB - The Type 1 family of growth factor receptors includes epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3 and c-erbB-4. Overexpression of the first two members is associated with poorer prognosis in patients with breast carcinoma. In this study we examined the expression of c-erbB-4 protein using the monoclonal antibody HFR-1. A total of 127 consecutive cases of primary operable invasive breast carcinoma presenting between 1975 and 1977 were studied. All patients were managed by simple mastectomy or conservation surgery with radiotherapy and no adjuvant therapy given. Long-term follow-up was maintained. Routine, formalin-fixed, paraffin-embedded tumour samples were used and sections were stained immunohistochemically using the Duet StreptABC method. Immunoreactivity was classified using a simple semi-quantitative scoring method. Protein expression was generally low but definite positive cytoplasmic, membranous and nuclear reactivity was identified in 58%, 41% and 25% of cases respectively. Expression at all three sites demonstrated significant inverse associations were histological grade. In addition, membrane accentuation correlated inversely with the Nottingham Prognostic Index (NPI), while cytoplasmic reactivity showed a positive association with c-erbB-3 expression. No significant associations were found with disease-free interval or survival. The results of this study demonstrate that higher levels of c-erbB-4 protein expression are associated with a more differentiated histological phenotype in contrast to the other members of the Type 1 family. Larger series with extended follow-up will be required to ascertain definitively the prognostic value of c-erbB-4 expression in breast carcinoma. (C) 2000 Cancer Research Campaign.

KW - Breast cancer

KW - c-erbB-4

KW - Growth factor receptor

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0034053352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034053352&partnerID=8YFLogxK

M3 - Article

C2 - 10735500

AN - SCOPUS:0034053352

VL - 82

SP - 1163

EP - 1170

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -